Merck has signed a Memorandum of Understanding (MoU) with Synplogen, a startup spun out of Kobe University's Graduate School of Science, Technology and Innovation.
Small biotechs are turning to single-use to retain ownership of their manufacturing processes, says Merck Millipore as industry predicts continued double-digit growth for such systems.
Merck Millipore has entered an agreement whereby it will control and manage the Singulex Life Science Research business, which offers a technology that can provide ultra-sensitive protein detection.
Merck KGaA has continued its diversification effort with a $17bn (€13bn) bid for Sigma Aldrich that will see it battle Thermo Fisher and GE Healthcare for a share of the life sciences tools and supplies market.
Merck Millipore has set out to win more biomanufacturing business in Japan by consolidating testing and technical operations in the country into a newly expanded Tokyo training hub.
The global bioseparation systems market is projected to almost double in size from $3.25B in 2012 to $6B in 2018, at a compound annual growth rate of about 11%, according to a recent report on the market.
Merck Millipore hopes the promise of reducing the number of experiments needed during process development will win customers for its new MAb development kit.
March has already been a busy month for the biomanufacturing technology sector and here is in-Pharmatechnologist.com’s round-up of some of the developments so far.
Biosimilars should help Millipore achieve long-term growth but cancellation of an insulin contract and rising raw material costs hit second quarter results.